You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma
|
|---|---|
| Published in |
BMC Medicine, June 2017
|
| DOI | 10.1186/s12916-017-0851-3 |
| Pubmed ID | |
| Authors |
Jasper Wouters, Miguel Vizoso, Anna Martinez-Cardus, F. Javier Carmona, Olivier Govaere, Teresa Laguna, Jesuchristopher Joseph, Peter Dynoodt, Claudia Aura, Mona Foth, Roy Cloots, Karin van den Hurk, Balazs Balint, Ian G. Murphy, Enda W. McDermott, Kieran Sheahan, Karin Jirström, Bjorn Nodin, Girish Mallya-Udupi, Joost J. van den Oord, William M. Gallagher, Manel Esteller |
| Abstract |
Cutaneous melanoma is the deadliest skin cancer, with an increasing incidence and mortality rate. Currently, staging of patients with primary melanoma is performed using histological biomarkers such as tumor thickness and ulceration. As disruption of the epigenomic landscape is recognized as a widespread feature inherent in tumor development and progression, we aimed to identify novel biomarkers providing additional clinical information over current factors using unbiased genome-wide DNA methylation analyses. We performed a comprehensive DNA methylation analysis during all progression stages of melanoma using Infinium HumanMethylation450 BeadChips on a discovery cohort of benign nevi (n = 14) and malignant melanoma from both primary (n = 33) and metastatic (n = 28) sites, integrating the DNA methylome with gene expression data. We validated the discovered biomarkers in three independent validation cohorts by pyrosequencing and immunohistochemistry. We identified and validated biomarkers for, and pathways involved in, melanoma development (e.g., HOXA9 DNA methylation) and tumor progression (e.g., TBC1D16 DNA methylation). In addition, we determined a prognostic signature with potential clinical applicability and validated PON3 DNA methylation and OVOL1 protein expression as biomarkers with prognostic information independent of tumor thickness and ulceration. Our data underscores the importance of epigenomic regulation in triggering metastatic dissemination through the inactivation of central cancer-related pathways. Inactivation of cell-adhesion and differentiation unleashes dissemination, and subsequent activation of inflammatory and immune system programs impairs anti-tumoral defense pathways. Moreover, we identify several markers of tumor development and progression previously unrelated to melanoma, and determined a prognostic signature with potential clinical utility. |
X Demographics
The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 8 | 33% |
| United Kingdom | 3 | 13% |
| Chad | 1 | 4% |
| Netherlands | 1 | 4% |
| Japan | 1 | 4% |
| Portugal | 1 | 4% |
| Mexico | 1 | 4% |
| Belgium | 1 | 4% |
| Unknown | 7 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 20 | 83% |
| Scientists | 3 | 13% |
| Practitioners (doctors, other healthcare professionals) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Unknown | 74 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 17 | 23% |
| Researcher | 15 | 20% |
| Student > Bachelor | 9 | 12% |
| Student > Master | 6 | 8% |
| Other | 4 | 5% |
| Other | 11 | 15% |
| Unknown | 13 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 23 | 31% |
| Medicine and Dentistry | 15 | 20% |
| Immunology and Microbiology | 5 | 7% |
| Agricultural and Biological Sciences | 4 | 5% |
| Veterinary Science and Veterinary Medicine | 2 | 3% |
| Other | 10 | 13% |
| Unknown | 16 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 February 2018.
All research outputs
#1,110,948
of 24,892,887 outputs
Outputs from BMC Medicine
#789
of 3,882 outputs
Outputs of similar age
#22,475
of 322,655 outputs
Outputs of similar age from BMC Medicine
#13
of 51 outputs
Altmetric has tracked 24,892,887 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,882 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.2. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,655 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.